pubmed.ncbi.nlm.nih.gov

A Narrative Review of Aspirin Resistance in VTE Prophylaxis for Orthopaedic Surgery - PubMed

Review

A Narrative Review of Aspirin Resistance in VTE Prophylaxis for Orthopaedic Surgery

Nameer van Oosterom et al. Drugs. 2020 Dec.

Abstract

Total hip arthroplasties (THA) and total knee arthroplasties (TKA) confer one of the highest risks for developing venous thromboembolism (VTE) and pharmacological prophylaxis is imperative to help mitigate the risks. Aspirin is the most cost-effective medication for VTE prophylaxis, and its use post-THA/TKA has grown in popularity. Aspirin resistance is categorised as clinical or laboratory resistance with obesity, advancing age, diabetes mellitus, dyslipidaemia and inflammatory diseases identified as risk factors for aspirin resistance. Treatment failure due to aspirin resistance has been reported in cardiovascular and cerebrovascular disease leading to increased rates of mortality and re-embolisation. However, aspirin resistance in patients undergoing a THA/TKA has not been described, nor has there been investigation into the incidence rates or clinical outcomes. The aim of this narrative review is to appraise the concept of aspirin resistance in the context of aspirin use for VTE prophylaxis after THA/TKA surgeries. This is important to investigate as the risk factors for aspirin resistance, including obesity, advancing age, diabetes mellitus, dyslipidaemia and inflammatory diseases, are also risk factors for THA/TKA and risk factors for VTE. The presence of aspirin resistance in patients undergoing orthopaedic surgery may place patients at greater risk of thrombotic events if aspirin is prescribed for VTE prophylaxis. This could further increase the risk of complications associated with VTE and potential long-term consequences such as post-thrombotic syndrome. Future research is required to explore and quantify the rates of aspirin resistance and the clinical outcomes in orthopaedic patients; especially in those patients with these overlapping risk factors for THA/TKA, VTE and aspirin resistance.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. Am J Med. 2013;126(9):832e13–e21. https://doi.org/10.1016/j.amjmed.2013.02.024 . - DOI
    1. Piazza G, Hohlfelder B, Goldhaber SZ. Handbook for venous thromboembolism. Cham: Springer International Publishing; 2015. - DOI
    1. Australian Government. Venous thromboembolism clinical fact sheet. Australian Commission on Safety and Quality in Health Care. 2018. https://www.safetyandquality.gov.au/wp-content/uploads/2018/03/Venous-th... . Accessed August 2019.
    1. Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism. Med J Aust. 2019;210(5):227–35. https://doi.org/10.5694/mja2.50004 . - DOI - PubMed
    1. Bala A, Huddleston J, Goodman S, Maloney W, Amanatullah D. Venous thromboembolism prophylaxis after TKA: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? Clin Orthop Related Res. 2017;475(9):2205–13. https://doi.org/10.1007/s11999-017-5394-6 . - DOI

Publication types

MeSH terms

Substances

LinkOut - more resources